Literature DB >> 9747227

[Allogeneic bone marrow transplantation in congenital erythropoietic porphyria. Gunther's disease].

C Lagarde1, D Hamel-Teillac, Y De Prost, S Blanche, C Thomas, A Fischer, Y Nordmann, C Ged, H De Verneuil.   

Abstract

INTRODUCTION: The congenital erythropoietic porphyria (Günther's disease) (CEP) is a rare autosomal recessively metabolic disease due to the deficit of uroporphyrinogen III cosynthetase, fourth enzyme of the porphyrin-heme biosynthesis. This disease is characterized by severe cutaneous photosensitivity with profound skin lesions, hemolytic anemia and excess of uroporphyrin I excretion. The vital prognosis is very bad and until now, no treatment seems to be efficient. Bone marrow transplantation seems to be able to correct the enzymatic deficit that causes the disease because it is located in the bone marrow. OBSERVATION: We report the case of a four and a half year old girl who received an allogeneic bone marrow transplantation (BMT) at the age of two. Despite an encouraging result, the first transplantation failed. A second allogeneic transplantation was attempted eight months later with the same HLA identical heterozygous donor and bone marrow engrafment succeeded. Twenty one months after the second bone marrow transplantation, clinical and biological results are still excellent. DISCUSSION: No classical treatment of CEP really proved its efficiency and no one was curative. CEP resulting from an homozygous deficiency in uroporphyrinogen III cosynthetase, enzyme that takes part in the porphyrin-heme biosynthesis which is principally located in the erythropoietic system of the bone marrow, substitution of this defective lineage by BMT was a very attractive treatment to correct this anomaly. The first bone marrow transplantation attempted on an affected child in 1990 in Manchester failed because the patient died of infections complications. After the failure of the first transplantation, our little patient is now healed twenty one months after the second BMT and biochemical anomalies are corrected. If a long follow up is necessary to appreciate the long-term efficiency of this treatment, allogenic bone marrow transplantation seems to cure Günther's disease and must be proposed as the treatment of this affection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9747227

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  6 in total

1.  Intracellular rescue of the uroporphyrinogen III synthase activity in enzymes carrying the hotspot mutation C73R.

Authors:  Arola Fortian; Esperanza González; David Castaño; Juan M Falcon-Perez; Oscar Millet
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

2.  Successful match-unrelated donor bone marrow transplantation for congenital erythropoietic porphyria (Günther disease).

Authors:  Sophie Dupuis-Girod; Véronique Akkari; Cécile Ged; Claire Galambrun; Kamila Kebaïli; Jean-Charles Deybach; Alain Claudy; Lucette Geburher; Noël Philippe; Hubert de Verneuil; Yves Bertrand
Journal:  Eur J Pediatr       Date:  2004-11-20       Impact factor: 3.183

3.  Mutational analysis of uroporphyrinogen III cosynthase gene in Iranian families with congenital erythropoietic porphyria.

Authors:  Meysam Moghbeli; Mahmood Maleknejad; Azadeh Arabi; Mohammad Reza Abbaszadegan
Journal:  Mol Biol Rep       Date:  2012-02-18       Impact factor: 2.316

4.  Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells.

Authors:  Elodie Robert-Richard; François Moreau-Gaudry; Magalie Lalanne; Isabelle Lamrissi-Garcia; Muriel Cario-André; Véronique Guyonnet-Dupérat; Laurence Taine; Cécile Ged; Hubert de Verneuil
Journal:  Am J Hum Genet       Date:  2008-01       Impact factor: 11.025

5.  Metabolic correction of congenital erythropoietic porphyria with iPSCs free of reprogramming factors.

Authors:  Aurélie Bedel; Miguel Taillepierre; Véronique Guyonnet-Duperat; Eric Lippert; Pierre Dubus; Sandrine Dabernat; Thibaud Mautuit; Bruno Cardinaud; Catherine Pain; Benoît Rousseau; Magalie Lalanne; Cécile Ged; Yann Duchartre; Emmanuel Richard; Hubert de Verneuil; François Moreau-Gaudry
Journal:  Am J Hum Genet       Date:  2012-07-13       Impact factor: 11.025

6.  Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells.

Authors:  Florence Prat; Jérôme Toutain; Julian Boutin; Samuel Amintas; Grégoire Cullot; Magalie Lalanne; Isabelle Lamrissi-Garcia; Isabelle Moranvillier; Emmanuel Richard; Jean-Marc Blouin; Sandrine Dabernat; François Moreau-Gaudry; Aurélie Bedel
Journal:  Stem Cell Reports       Date:  2020-08-13       Impact factor: 7.765

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.